Siemens Healthcare Diagnostics Products Gmbh

Dade Behring Marburg Gmbh

Frank Vitzthum

Stefan Teigelkamp

Harald Althaus

Konrad Braun

Norbert F Zander

Carsten Schelp

Andreas Kappel

Bodo Fischer

Andrea Lichte

Matthias Ehm

Sabine Teigelkamp, Legal Representative

Roland Barten

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PlGF), especially antibodies directed against the placental growth factor, and production and use thereof.

The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2.

Antibodies for determining the prothrombin fragment F2/F1+2 in a homogeneous immunoassay

The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent. The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.

Blood coagulation assays

The invention relates to antibodies directed against F, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the Ffragment of prothrombin.

Growing community of inventors

Niederwalgern, Germany

Stefan Teigelkamp